Effective January 1, 2017 - New permanent J-code for ONIVYDE®: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-6225

NCCN Recommendation as a Category 1 Treatment Option

Liposomal irinotecan (ONIVYDE®) + 5-FU/LV is the only Category 1 option for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression1

Tumor type Line of therapy NCCN
recommendation
NCCN category
Tumor type Metastatic
pancreatic cancer
Line of therapy Second-line, with
previous gemcitabine-
based therapy
NCCN
recommendation
5-FU + leucovorin +
liposomal irinotecan
for patients with
metastatic pancreatic
cancer who have a
good performance
status*
NCCN category 1

ECOG=Eastern Cooperative Oncology Group; PS=performance status.

*ECOG 0-1, patent biliary stent, and adequate nutritional intake.

Therapies are categorized on the following rating system based on National Comprehensive Cancer Network® (NCCN®) categories of evidence and consensus. 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate; 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. All recommendations are category 2A unless otherwise noted.

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

Reference: 1. NCCN Guidelines Version V.2.2017, 07/20/17 © National Comprehensive Cancer Network, Inc. 2017. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.2.2017. © National Comprehensive Cancer Network, Inc.; 2017. All rights reserved. Accessed July 20, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN® makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION